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Implementation of National Pediatric Guidelines

Abstract
Purpose: The purpose of this study was to assess the use of supplemental, as needed
(prn) pharmacologic interventions for uncontrolled acute chemotherapy induced nausea
and vomiting (CINV) in children with cancer after implementation of new pediatric
CINV prophylaxis guidelines. Description of Project: A retrospective chart review was
completed on forty-three children admitted to the hospital for chemotherapy during a 3
month period in 2017 to document the use of medications given for acute breakthrough
CINV. The pre-implementation group received anti-emetics based on the institutional
standard of care. A second retrospective chart review was completed on thirty-three
children admitted to the hospital for chemotherapy during a 3 month period in 2018 to
evaluate use of medications for acute breakthrough CINV. The post-implementation
group received anti-emetics based on the new published pediatric guidelines. Patient
characteristics, treatment information, and provider compliance with guidelines were
collected. Results/Conclusions: Implementation of the guideline by the institution was
successful with 91% of patients in the post-intervention group receiving the new antiemetic regimen to prevent nausea and vomiting. The mean anti-emetic dose in all
patients for breakthrough CINV pre-implementation was 4.837±10.4857. Postimplementation, the mean anti-emetic dose for all patients was 3.394±6.432. This was not
statistically significant (p =0.462). For patients under 12, the mean anti-emetic dose preimplementation was 5.8±12.5333 and post-implementation was 3.882±8.1. This was also
not statistically significant (p =0.55). Data collected from this project did demonstrate a
decrease in the number of breakthrough anti-emetics used in children under 12 years of
age likely related to the addition of the drug aprepitant. Although clinical guidelines
provide excellence guidance to clinicians, they must always be evaluated for risk versus
benefit; adapted to individual patient circumstances as appropriate; and used within the
context of expert clinician judgement.
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Introduction
Childhood cancer is the second leading cause of death in children 5-14 (Ward,
DeSantis, Robbins, Kohler, & Jemal,2014). In the United states 1 in 285 children under
the age of 20 are diagnosed with cancer each year (Ward et al., 2014). Chemotherapy
induced nausea and vomiting (CINV) is a common side effect that can cause significant
physical and emotional distress. Chemotherapy induced nausea and vomiting can be
divided into different categories. Acute nausea and vomiting includes all episodes each
day the chemotherapy is administered, and for 24 hours after the last dose. Delayed
nausea and vomiting starts 24 hours after the last dose and can last up to one week.
Anticipatory nausea and vomiting occurs prior to chemotherapy administration. It can be
triggered by smells, tastes, and anxiety (Jordan, Kasper, & Schmoll, 2005).There are
many risk factors that are associated with a higher incidence of CINV. These include but
are not limited to female gender, younger age, and previous exposure to highly
emetogenic agents (Haiderali, Menditto, Good, Teitelbaum, &Wegner, 2011).
Chemotherapy agents classified as highly emetogenic have a greater than 90%
frequency of emesis in the absence of prophylaxis (Dupuis et al. 2013). The majority of
patients at some time point in their cancer treatment protocol will receive chemotherapy
classified as highly emetogenic. Uncontrolled nausea or vomiting from chemotherapy
causes not only a burden on the patient, it can also impact the overall quality of care
provided. Some of the direct costs that are associated with managing nausea or vomiting
symptoms include: additional anti-emetic medications; unplanned doctor visits;
unexpected hospitalizations, and visits to the emergency room. Indirect costs of CINV
include loss of work productivity, and missed work for patient and/or caregiver
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(Haiderali et al., 2011). In a study by Haiderali et al. (2011), it was estimated that the
combined indirect and direct cost of CINV per patient per round of chemotherapy was on
average $778.53 per patient. This number only accounts for the cycle of chemotherapy.
The standard of care for children with Ewing’s sarcoma is 12 cycles of highly emetogenic
chemotherapy. That would mean an increased cost of around $9342.36 per patient with
this diagnosis each year.
CINV is one of the most feared side effects prior to chemotherapy treatment, and
unfortunately it is relatively common. Anti-emetic medications to control the unwanted
effects of chemotherapy are available, but they are not always administered according to
international guidelines. Insufficient administration of anti-emetics can lead to
suboptimal management of side effects resulting in a significant impact on quality of life
(QoL) (Lorusso et al., 2016) Many studies have shown that CINV negatively affects QoL
in patients receiving treatment for malignancy. In a study by Ballatori et al. (2007), more
than 90% of the patients at 7 different Italian centers with acute and delayed onset CINV
reported impact on daily life on the Functional Living Index-Emesis (FLIE)
questionnaire. The FLIE questionnaire is the only validated nausea and vomiting specific
patient reported outcome tool.
Until recently, there had been no pediatric published guidelines for management
and prophylaxis of CINV. In 2013, The Pediatric Oncology Group of Ontario (POGO)
published evidence based guidelines for management of CINV in pediatric cancer
patients. In 2016, the Children’s Oncology Group (COG) the national pediatric clinical
trial organization supported by the National Cancer Institute (NCI) adopted these
evidence based guidelines for CINV management. These guidelines have since been
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amended in 2017. One of the biggest changes in the 2017 guidelines was the use of the
drug aprepitant for children greater than 6 months of age. These changes were based on
recommendations of Patel et al., (2017). Aprepitant is an anti-emetic medication designed
to treat delayed vomiting, however the original FDA approval for this medication was in
the adult population and in adolescents greater than 12 years. These evidence based
guidelines give health care providers an approach to help reduce the incidence of both
acute and delayed nausea and vomiting caused by chemotherapy in the pediatric
population (Dupuis et al., 2013).
Purpose
The purpose of this project was to evaluate if there was a decrease in the use of
supplemental pharmacologic intervention to treat breakthrough acute CINV after
implementation of new adapted St. Louis Children’s Hospital (SLCH) guidelines based
on a published evidenced-based national guideline. The guideline was expected to have
the most impact on children less than 12 years of age, thus this group was analyzed
separately. The second purpose was to assess provider compliance with the new
guideline. The scope of this project includes only those patients who received highly
emetic chemotherapy; and the data collection occurred only during the acute phase of
CINV including all days the patient actually received chemotherapy.
The standard definition in the literature for optimal control of acute CINV is stated
as: no vomiting, no retching, no nausea, and no use of anti-emetic agents other than those
given for CINV prevention. This level of control is to be achieved on each day of
chemotherapy administration. For this project, each time a patient received an anti-emetic
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in a 24 hour period, was considered a failure of the regimen at that point in time. Each
dose of breakthrough anti-emetics was counted for each day of chemotherapy for all
patients in the sample.
Setting
This project was completed at a large urban academic pediatric hospital. The
hospital has a nationally recognized pediatric oncology program and is an active member
of the COG. The hospital had developed an institutional standard of care for prophylaxis
of both acute and delayed vomiting caused by chemotherapy including a defined
breakthrough regimen. This institutional standard was based on the adult American
Society of Clinical Oncology (ASCO) guideline (Basch et al., 2011) and the published
literature regarding symptom management of pediatric patients receiving chemotherapy.
The institutional standard was implemented with a general pre-built anti-emetic order set
with clinical guidance, but it was ultimately left up to the providers to prescribe as they
desired for their patient’s individual needs and preferences.
Anti-Emetic Medications
There are 3 major categories of anti-emetic agents that will be discussed in this
project. 5- HT3 receptor antagonists such as ondansetron are the mainstay of treatment
for acute CINV. Corticosteroids such as dexamethasone enhance the activity of
ondansetron and are given concurrently. Neurokinin 1 receptor antagonists such as
aprepitant augment the anti-emetic regimen and primarily treat delayed vomiting. The
standard of care for anti-emetics previous to dissemination of the new COG guidelines
was to prescribe ondansetron for prophylaxis of CINV scheduled every 6 hours during

6

Implementation of National Pediatric Guidelines
each day of chemotherapy and for 24-48 hours afterward. Aprepitant, to prevent delayed
vomiting, was prescribed for patients older than 12 years of age. For patients that were
able to receive steroids, dexamethasone was given every 24 hours. Diphenhydramine and
metoclopramide were used as second line for breakthrough nausea and vomiting, and
lorazepam was used as third line treatment for breakthrough symptoms. The timing and
dosing of this standard anti-emetic regimen was based on adult guidelines; published
pediatric studies; and institutional provider preference related to adverse events from
these medications.
A multi-disciplinary task force at the pediatric hospital (where the data was
collected) reviewed the new pediatric anti-emetic guidelines and the associated evidence.
The team decided to implement the guidelines with a few minor deviations based on the
level of evidence; clinical contributions from team members; and the potential for
increased toxicity. The guidelines endorsed by the Children’s Oncology Group were
adapted and then disseminated to the hematology/oncology division at Saint Louis
Children’s Hospital (SLCH) in October of 2017 as a new adapted anti-emetic guideline.
The differences in the COG guidelines and the new SLCH adapted guideline are outlined
in Table 1. In these adapted guidelines the interval of administration of dexamethasone
for anti-emetic prophylaxis was changed from the recommended every 6 hour to every 12
hours. The task force intentionally modified this recommendation for dexamethasone as
the published evidence review was graded, and every 6 hour dosing was a weak
recommendation with a low quality of evidence (for highly emetic chemotherapy agents).
Evidence Identification and Synthesis
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A review of the literature regarding the previous standard of antiemetic regimens
to control CINV in pediatric patients was performed. The search terms used were:
therapeutics, child, nausea, oncology or cancer. The National Center for Biotechnology
Information (NCBI) database and PubMed were searched using these terms with the
filters of less than 18 years old and only articles in English. There were 67 results to be
screened after duplicates were removed. Of these 67 results, 56 record were excluded for
titles and abstracts not applicable. Eleven full articles were assessed for eligibility. Six
records were included in the synthesis.
In the study published by Cubeddu, Hoffmann, Fuenmayor, & Finn (1990), the
efficacy of ondansetron to treat CINV in a double blind randomized controlled trial was
evaluated. This study demonstrated that ondansetron was superior to a placebo in all
aspects of antiemetic efficacy. This historical study was included in the synthesis as it set
the standard for ondansetron as the mainstay of antiemetic therapy for pediatric patients
receiving chemotherapy. There were no more recent studies evaluating the efficacy of
ondansetron in CINV; and 5-HT3 antagonists (like ondansetron) remain the backbone of
ASCO and POGO recommendations for control of CINV.
Anti-emetic agents given in combination with ondansetron have been inconsistent
in pediatric oncology practice even though there is data to suggest that multi-agent
treatment for CINV is the most efficacious. The Oncology Nursing Society (ONS) has
published practice recommendations that are applicable to the pediatric population that
include 5-HT3 (ondansetron or second generation drug) for prophylaxis of CINV
(Oncology Nursing Society, 2014). Triple drug therapy with 5-HT3 agonist,
dexamethasone, and aprepitant is the adult standard of care in ONS guidelines. A meta-
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analysis of antiemetic medications for the prevention and treatment of CINV concluded
that 5-HT3 antagonists remain the gold standard and are more effective than older agents,
and that the addition of dexamethasone to this regimen improves efficacy (Phillips et al.,
2016). Aprepitant is a newer medication that is recommended for adults receiving
chemotherapy in addition to 5-HT3 antagonists and dexamethasone. There was limited
data regarding aprepitant in pediatric patients and previous to the new COG guidelines, it
was not recommended for children under the age of 12 years. A study of aprepitant was
completed in 2014 to assess the effect and safety of aprepitant in children receiving
highly emetogenic chemotherapy. The results of this study concluded that much like
adult data has shown, aprepitant is a safe and effective drug that significantly decreases
CINV in pediatric patients when used in conjunction with dexamethasone and
ondansetron (Bakhshi et al., 2015).
A second literature review was performed regarding the adoption and use of new
evidence based guidelines by healthcare providers. The search terms used were: barriers
or obstacles, provider, guidelines or protocols, implementation. These terms were used to
search the Medline database. A total of 251 records were identified and screened. Two
hundred thirty seven records were excluded for title or by abstract. Fourteen full text
articles were assessed for eligibility. Only records in English were evaluated.
According to Okene & Zapka (2000) despite dissemination of clinical practice
guidelines, adherence to these guidelines for clinical care is often low. Inconsistent use of
clinical practice guidelines remains a continued challenge to improve public health (Chan
et al., 2017). There are many barriers to implementation of clinical practice guidelines.
Some providers do not believe there is a need for a change in clinical standards that are
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well established. Although many studies have shown that evidence based guidelines
and/or clinical practice guidelines can have a positive impact on patient outcomes, many
clinicians do not readily accept changes to their current practice (Okene & Zapka, 2000).
Improved dissemination and education could improve provider compliance to evidence
based practice guidelines (Okene & Zapka, 2000). A study by Zeng et al. (2017) showed
that even though providers were aware of clinical practice guidelines, only a small
percentage of them implemented the findings. Of the providers surveyed, the most
frequently reported barriers to guideline implantation were: lack of training, lack of
access, and lack of awareness. Although there is scant literature regarding barriers to
clinical practice guideline implementation, what does exist reflects that a lack of
knowledge and education on the guidelines remain the primary barriers to changing
practice.
Method
The overall design of this project was a retrospective chart review to evaluate the
adherence to implementation of the new pediatric guideline; and to assess outcomes for
patients who were treated according to the new guideline. Documentation of
“breakthrough” medications was used as the key outcome measure to assess if the
guideline medications worked as intended to control all symptoms of nausea and
vomiting after chemotherapy. The adapted guidelines were disseminated to the
hematology/oncology division at SLCH in October of 2017. Charts at this single
institution were reviewed for patients who received chemotherapy during a planned
chemotherapy admission between January 2017 and March 2017. Inclusion criteria for
the chart review included all planned admissions with a patient receiving chemotherapy
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classified as highly emetogenic per COG anti emetic guidelines. Exclusion criteria for the
chart review were the following: outpatient chemotherapy treatments; patients that
received therapy categorized as moderately or mildly emetogenic as delineated in the
COG antiemetic guidelines; patients that were unable to receive 5-HT3 antagonist for
comorbid conditions such as prolonged QT; and patients unable to receive steroids.
Conditions for which steroids are contraindicated as prophylaxis for CINV include but
are not limited to: patients receiving therapy for leukemia, patients being treated for brain
tumors, and comorbid conditions such as avascular necrosis.
The patients who were admitted from January 1, 2017- March 31, 2017 were
accessed through a list of pre-certifications for insurance approval on a shared drive
within the division. All patients that were directly admitted to the inpatient oncology
service, or admitted through the outpatient oncology clinic were on this master list. These
patients were screened for any exclusion criteria. Patients that had more than one
admission within this time frame were treated as separate encounters for the chart review.
The same lists was accessed for January 1, 2018- March 31, 2018. For both chart reviews
all patients were screened for: administration of chemotherapy categorized as highly
emetogenic; greater than 6 months of age as this is the youngest patient able to receive
aprepitant; and no contraindications for use of ondansetron or dexamethasone. These
contraindications included, but are not limited to: prolonged QTc and allergy to 5-HT3
agonists.
Each patient chart that met criteria for inclusion had the following data extracted
from the chart: age, gender, number of days patient admitted for treatment, and number
and type of PRN medications received for breakthrough CINV. In the review of the first
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quarter of 2018, it was evaluated if the guidelines were followed when prescribing the
chemotherapy for each admission, and if that provider was an APN or MD. Results were
tracked using the data collection tool (Appendix A). All patient identifiers were removed.
Each patient chart was only accessed once. Data was numbered sequentially starting with
number 1. Data collected from patient charts from January1, 2017- March 31, 2017 will
be coded with the letter “a” following the number. Data collected from patient charts
from January 1, 2018-March 31, 2018 will be coded with the letter “b” after the number.
Results
Seventy-six patient’s charts met eligibility criteria and underwent review. Fortythree of those charts were patient admissions between January 1, 2017 and March 31,
2017. The remaining thirty-three charts reviewed were patient admissions between
January 1, 2018 and March 31, 2018. In 2017, the sample included 58%, and 58% of the
children were less than twelve years old. In 2018, the sample included 64%; and 52% of
the children were less than twelve years old. The mean age of patients in 2017 was
9.07±6.19; and in 2018 the mean patient age was 9.47±6.15.
A t-test was used to compare the mean number of combined anti-emetic doses for
all patients in the first quarter of 2017, with the sample from the first quarter of 2018. The
mean anti-emetic dose for breakthrough CINV in 2017 was 4.837±10.4857, and in 2018
the mean anti-emetic dose was 3.394±6.432. This was not statistically significant (p
=0.462) as shown in Table 3. It was then compared by the number of patients in each
sample. In the first quarter of 2017, 21 patients (49%) received anti-emetics for
breakthrough CINV as compared to 15 patients (46%) in 2018. A chi square was

12

Implementation of National Pediatric Guidelines
performed and this was found not to be statistically significant (p =0.77). Both of these
results are shown in Table 2.
The patients were then divided into two groups by age for additional analysis. The
age of 12 years was chosen as the new guideline had the greatest potential impact on
children less than 12 years of age who were now able to get three agents up front to
control their nausea and vomiting (ondansetron, dexamethasone and aprepitant). A t-test
was performed to compare the mean number of combined anti-emetic doses for patients
<12 years old in the first quarter of 2017, and in the first quarter of 2018. The mean antiemetic dose for 2017 was 5.8±12.5333; and in 2018 the mean was 3.882±8.1. This was
found to not be statistically significant (p =0.55) as shown in Table 4.
Conclusion
The data from this project did demonstrate that there was excellent adherence with
use of the new SLCH adapted pediatric anti-emetic guideline in this population of
patients. Of the 33 patient charts reviewed, 30 patients (91%) received anti-emetics
recommended in the adapted guideline. In reviewing the analysis of the need for antiemetic doses to treat breakthrough CINV, it can be concluded that in the population of
children evaluated in this project, there was not a statistically significant difference in
control of acute nausea/vomiting after implementation of the new adapted pediatric
guideline. This data may suggest that the previous institutional standard regimen at the
hospital was successful in managing acute nausea and vomiting prior to the
recommended changes in the new pediatric guideline. However, in the age group of
children less than 12 years of age, children did receive 2 fewer prn anti-emetic
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medications for breakthrough symptoms each admission for chemotherapy treatment
after guideline implementation. The small sample size in children less than 12 years
likely impacted the ability to achieve any statistical significance. Although the data in
the sample did not achieve statistical significance, this decrease in anti-emetics in
children less than 12 years of age is clinically significant. Fewer doses of breakthrough
medications for symptoms of nausea or vomiting would have significantly impacted the
patient’s overall CINV control; and their quality of life if this would have been an
outcome measure.
Discussion
One of the biggest changes in the new adapted pediatric guideline was a
significant increase in the dosing of dexamethasone (twice the dose). These findings
illustrate similar control of acute CINV with once daily dosing of dexamethasone as
opposed to the new guideline standard of every 12 hours. The acute side effects of
dexamethasone used for CINV were studied by Vardy, Chiew, Galica, Pond, & Tannock
(2006). The four symptoms reported were: insomnia, gastro-esophageal reflux, agitation
and depression. In fact, 27% of patients reported moderate to severe symptoms in two of
four categories in the weeks following dexamethasone administration; and 32% reported
moderate to severe symptoms in at least three of these categories. These severe side
effects from the anti-emetic itself may negatively impact quality of life. While the use of
dexamethasone has been well established as an effective agent to prevent both acute and
delayed nausea and vomiting, the unwanted side effects of increased doses may be
substantial without increased efficacy. CINV has negative effects on QoL, however,
there are many factors that affect QoL. Patients with minimal CINV may have decrease
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in QoL from the side effects of dexamethasone for CINV prophylaxis (Vardy et al, 2006).
Providers should take into consideration that a similar dose of dexamethasone once daily
in this population of patients, was just as effective as an every 12 hour dose for the
duration of therapy without the risk of increased adverse side effects secondary to high
dose steroid administration for CINV.
The second major change in the new pediatric guideline was the use of aprepitant
in all children older than 6 months of age. Aprepitant was designed to control delayed
vomiting in the time frame from 2-8 days post chemotherapy treatment. Previously,
patients younger than 12 years old, did not receive aprepitant for CINV. Although
aprepitant has been shown to be a highly effective ameliorator of delayed CINV, these
effects may not be seen while the patient is still admitted but would occur after the child
is discharged from the hospital. The prevalence of delayed vomiting in children after
moderately high or highly emetogenic chemotherapy was reported to be as high as 32%
in a study by Robinson & Carr (2007) specifically addressing the prevalence and pattern
of these symptoms in children. The data collected for this project was only during the
admission for actual treatment and did not include any post treatment follow up.
Although data collected in the project did not show a statistical difference in acute
vomiting control; the use of aprepitant in children is still highly recommended as the goal
is the prevention of delayed vomiting that occurs up to one week after treatment.
In terms of adaptation of the new pediatric guideline, the pediatric oncology team
was very successful with a greater than 90% compliance with the new recommendations.
Provider compliance with new evidence based guidelines has been well studied.
However, there is a paucity of literature on effective ways to increase use of guidelines in
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practice. Studies have shown 30-40% of patients do not receive medical care based on
scientific evidence, and 25-30% of care is not needed or potentially harmful (Grol &
Grimshaw, 2003). Barriers to provider use of guidelines at many different points of care.
These barriers exists at the level of the patient, the provider, the healthcare team, the
health care organization and the healthcare environment (Grol & Grimshaw, 2003). Lack
of knowledge by the provider continues to be the most studied barrier to new guideline
implementation (Maue, Segal, Kimberlan, & Lipowski, 2004).
The new adapted guidelines for the prophylaxis of CINV were disseminated via
division email and discussed at team meetings. There was no formal education on the use
of the new guidelines prior to or after dissemination. However, there were pre-built antiemetic order sets in the provider order entry system that provided clinical guidance on the
drugs and dosing directly from the new pediatric guidelines. Future interventions to
improve provider use of institutional guidelines could include focused education with
providers who are prescribers of chemotherapy. Increased education of bedside nurses
who are administering highly emetogenic chemotherapies may also be beneficial. The
bedside nurse could play a crucial role by recognition that a patient receiving highly
emetogenic chemotherapy was being undertreated for CINV and alert a provider.
Limitations
The findings of this study are limited by the review of patient charts at a single
institution, and by a small sample size. In addition, the incidence of nausea and vomiting
in young children may be effected by the child’s inability to verbalize nausea. Discomfort
in a child may be perceived by the caregiver as pain or general irritability, and therefore
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not treated. There are also limited validated tools in pediatrics to clearly assess and rate
the distressing symptoms of nausea for children of all ages.
Conclusions
CINV is a distressing symptom of treatment for cancer that negatively impacts the
patient’s quality of life. This side effect is equally as distressing for children as it is
adults. While treatment for CINV has been well studied in adults, there is less definitive
evidence for effective prevention in the pediatric population. Recent guidelines have
been published to specifically address prophylaxis of nausea and vomiting in children
receiving chemotherapy. Providers who prescribe anti-emetics for children receiving
highly emetic chemotherapy need to carefully review the current data; new published
guidelines; level of evidence; drug interactions; and side effect profile of available antiemetics, and make informed choices in the clinical care of their patients. As always,
individual tolerance and patient preference should be a part of clinical care. Process
measures and outcome measures after implementation of any new guideline are crucial to
follow the success of the implementation; and to continually improve the supportive care
we provide to both adults and children with cancer.
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Table 1. Changes to Anti-emetic prescribing recommendations.
Previous Institutional
Standard of Care

New Children’s Oncology
Group Guidelines

Ondansetron
Every 6 hours while receiving
chemotherapy

Ondansetron or Granisetron
Prior to initiation of
chemotherapy and then q 8
hours

Dexamethasone
0.2mg/kg every 24 hours if
unable to receive aprepitant.
0.1mg/kg every 24 hours if
concurrently receiving
aprepitant
Aprepitant
125mg on day 1 of
chemotherapy
80mg on days 2 & 3 of
chemotherapy only in patients
greater than 12 years old

Benadryl
PRN 1mg/kg every 6 hours
concurrently with
metoclopramide

Dexamethasone
6 mg/m2 every 6 hours if
unable to receive aprepitant
3 mg/m2 every 6 hours if
concurrently receiving
aprepitant
Aprepitant
125mg on day 1 of
chemotherapy or 3mg/kg for
patients old but greater than 6
months old and less than 12
years old
80mg on days 2&3 of
chemotherapy or 2mg/kg for
patients greater than 6 months
old and less than12 years old
and greater than 6 months old

*No recommendations for
breakthrough nausea and
vomiting*

Adapted Guidelines now used
at St. Louis Children’s
Hospital
Ondansetron
Every 6 hours while receiving
chemotherapy

Dexamethasone
6 mg/m2 every 12 hours if
unable to receive aprepitant
3 mg/m2 every 12 hours if
concurrently receiving
aprepitant
Aprepitant
125mg on day 1 of
chemotherapy or 3mg/kg for
patients old but greater than 6
months old and less than 12
years old
80mg on days 2&3 of
chemotherapy or 2mg/kg for
patients greater than 6 months
old and less than12 years old
and greater than 6 months old

Benadryl
PRN 1mg/kg every 6 hours
concurrently with
metoclopramide

Metoclopramide
PRN 0.3mg/kg every 6 hours

Metoclopramide
PRN 0.3mg/kg every 6 hours

Lorazepam
PRN 0.02mg/kg every 6 hours

Lorazepam
PRN 0.02mg/kg every 6 hours

22

Implementation of National Pediatric Guidelines
Table 2. T-Test Comparison of Mean Anti-Emetic Doses Between 2017 & 2018
Year
2017
2018

N
43
33

F

Equal
1.887
Variance
assumed
Equal
Variance
not
Assumed

Levine’s
Test for
Equality of
Variances
Sig.
t

0.174

Mean
Std. Deviation
Std. Error Mean
4.837
10.4857
1.599
3.394
6.432
1.1197
Independent Samples Test
T-Test for Equality of Means

df

Sig.

0.696

74

0.489

0.739

0.462

0.462

Mean
Std Error
95%
Difference Difference CI
Lower
1.4433
2.0739
2.6888

95%CI
Upper

1.4433

5.3357

1.9521

2.4492

5.5753

Table 3. Chi Square Comparison of Anti-Emetic Doses Between 2017 & 2018
Received AntiEmetics
Yes
No

2017 n(%)

2018 n(%)

p-value*

21 (49%)
22 (51%)

15(46%)
18(54%)

0.770

*Pearson Chi Square Test
Table 4. Comparison of Mean Anti-Emetic Doses Between 2017 & 2018 (<12 years old)
Year
2017
2018

N
25
17

Mean
5.8
3.882

Levine’s Test
for Equality
of Variance
F
Sig.

T

Df

Sig.

0.556

40

0.581

0.602

0.55

0.55

Equal
0.756
Variance
Assumed
Equal
Variance
Not
Assumed

0.39

Std. Deviation
Std. Error Mean
12.533
2.5067
8.1
1.9645
Independent Samples Test
T-Test for Equality of Means

Mean
Std. Error 95%
Difference Difference CI
lower
1.1976
3.4507
5.0566

95%
CI
upper
8.8919

1.9176

8.3546

3.1848

4.5193
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Appendix
Data Collection Form

Year ________

Chart # _________

Gender___________

Days in hospital __________

Number of doses of:
Benadryl_________
Metoclopramide_____________
Lorazepam____________

 Used anti-emetic prescribing guidelines

 Did not use anti-emetic prescribing guidelines
o Greater than 6 months and did not receive aprepitant
o Did not get correct steroid dose/interval

Age_________

